- Home
- GLPG vs VTMX Comparison
GLPG vs VTMX Comparison
Compare GLPG & VTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- VTMX
- Stock Information
- Founded
- GLPG 1999
- VTMX 1998
- Country
- GLPG Belgium
- VTMX Mexico
- Employees
- GLPG N/A
- VTMX N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- VTMX
- Sector
- GLPG Health Care
- VTMX
- Exchange
- GLPG Nasdaq
- VTMX Nasdaq
- Market Cap
- GLPG 2.1B
- VTMX 2.4B
- IPO Year
- GLPG 2005
- VTMX 2023
- Fundamental
- Price
- GLPG $33.24
- VTMX $26.50
- Analyst Decision
- GLPG Sell
- VTMX Sell
- Analyst Count
- GLPG 3
- VTMX 2
- Target Price
- GLPG $26.00
- VTMX $29.50
- AVG Volume (30 Days)
- GLPG 162.5K
- VTMX 99.3K
- Earning Date
- GLPG 10-29-2025
- VTMX 10-23-2025
- Dividend Yield
- GLPG N/A
- VTMX 2.50%
- EPS Growth
- GLPG N/A
- VTMX N/A
- EPS
- GLPG N/A
- VTMX 0.04
- Revenue
- GLPG $323,674,692.00
- VTMX $263,061,301.00
- Revenue This Year
- GLPG $1.77
- VTMX $12.94
- Revenue Next Year
- GLPG N/A
- VTMX $10.26
- P/E Ratio
- GLPG N/A
- VTMX $68.73
- Revenue Growth
- GLPG 5.43
- VTMX 11.49
- 52 Week Low
- GLPG $22.36
- VTMX $21.30
- 52 Week High
- GLPG $33.86
- VTMX $30.07
- Technical
- Relative Strength Index (RSI)
- GLPG 58.22
- VTMX 34.19
- Support Level
- GLPG $31.49
- VTMX $26.68
- Resistance Level
- GLPG $33.63
- VTMX $27.31
- Average True Range (ATR)
- GLPG 0.68
- VTMX 0.50
- MACD
- GLPG 0.01
- VTMX -0.17
- Stochastic Oscillator
- GLPG 85.82
- VTMX 15.15
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.